Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of OP-10 for recurrent or progressive glioma
jRCT2080225115Phase 2Completed
- Sponsor
- Ohara Pharmaceutical Co., Ltd.
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dordaviprone in glioma and diffuse midline glioma (DMG) (2 arms), sponsored by Ohara Pharmaceutical Co., Ltd. Started Mar 2020; status: completed.
02
Drugs
dordaviprone
03
Conditions
gliomadiffuse midline glioma (DMG)
Beyond the preview
Go deeper on jRCT2080225115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225115.